Dermata Therapeutics, INC 8-K filings

Dermata Therapeutics has successfully completed a $3.5 million private placement to fund its ongoing research and development of treatments for skin diseases.

Dermata Therapeutics announced progress in its Phase 3 clinical trial for DMT310, ongoing partnership discussions for DMT410, and a $2.3 million capital raise in the second quarter of 2024.

Dermata Therapeutics has increased its at-the-market offering by $505,000, bringing the total potential raise to $1,662,761.

Dermata Therapeutics has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $1,157,761 of its common stock through an at-the-market offering.

Dermata Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a prior non-compliance issue.

Dermata Therapeutics received a notice of non-compliance from Nasdaq regarding publicly held shares but quickly regained compliance within days.

Dermata Therapeutics has entered into agreements for the immediate exercise of outstanding warrants, generating approximately $2.66 million in gross proceeds and issuing new warrants in a private placement.

Dermata Therapeutics reports progress on its acne clinical trial and botulinum toxin partnership discussions, along with first quarter 2024 financial results.

Dermata Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement and will implement a 1-for-15 reverse stock split.

Dermata Therapeutics will implement a 1-for-15 reverse stock split effective May 16, 2024, to increase its share price.

Dermata Therapeutics' stockholders approved an increase to the company's equity incentive plan and a reverse stock split at the 2024 Annual Meeting.

Dermata Therapeutics initiated a Phase 3 clinical trial for its acne treatment, DMT310, and reported its full year 2023 financial results, including a cash balance of $7.4 million.

Dermata Therapeutics successfully obtained shareholder approval for a warrant issuance, ratified their auditor, and approved a measure for potential meeting adjournment at a special meeting held on January 12, 2024.